Antimicrobial resistance in Acinetobacter baumannii is a growing public health concern and an important pathogen in nosocomial infections. We investigated the genes involved in resistance to carbapenems and cephalosporins in clinical A. baumannii isolates from a tertiary medical centre in Malaysia. A. baumannii was isolated from 167 clinical specimens and identified by sequencing of the 16S rRNA and rpoB genes. The MIC for imipenem, meropenem, ceftazidime and cefepime were determined by the E-test method. The presence of carbapenemase and cephalosporinase genes was investigated by PCR. The isolates were predominantly nonsusceptible to carbapenems and cephalosporins (.70 %) with high MIC values. ISAba1 was detected in all carbapenem-nonsusceptible A. baumannii harbouring the bla OXA-23-like gene. The presence of bla OXA-51-like and ISAba1 upstream of bla OXA-51 was not associated with nonsusceptibility to carbapenems. A. baumannii isolates harbouring ISAba1-bla ADC (85.8 %) were significantly associated with nonsusceptibility to cephalosporins (P,0.0001). However, ISAba1-bla ADC was not detected in a minority (,10 %) of the isolates which were nonsusceptible to cephalosporins. The acquired OXA-23 enzymes were responsible for nonsusceptibility to carbapenems in our clinical A. baumannii isolates and warrant continuous surveillance to prevent further dissemination of this antibiotic resistance gene. The presence of ISAba1 upstream of the bla ADC was a determinant for cephalosporin resistance. However, the absence of this ISAba1-bla ADC in some of the isolates may suggest other resistance mechanisms and need further investigation.
INTRODUCTION
Acinetobacter baumannii has the ability to acquire resistance genes and survives for a long time in the hospital environment (Towner, 2000) . It is recognized as an important pathogen causing nosocomial infections such as bacteraemia and ventilator-associated pneumonia, especially in patients hospitalized in ICUs (Munoz-Price & Weinstein, 2008; Peleg et al., 2008) . Carbapenems have been shown to be the most active antibiotics against many multi-resistant strains. However, the emergence of Acinetobacter spp. which are resistant to carbapenems has been identified commonly in hospitals worldwide Dijkshoorn et al., 2007) . The mechanisms of resistance to carbapenems in Acinetobacter spp. include permeability changes in outermembrane proteins and penicillin-binding proteins, activation of efflux pumps and hydrolysis by b-lactamases (Peleg et al., 2008) . The production of carbapenemases in most of the carbapenem-resistant A. baumannii is due to the carbapenem-hydrolysing class D b-lactamases. The OXAtype carbapenemases, which are members of class D blactamases, are classified into five subgroups. Four of the subgroups are acquired carbapenemases, which include OXA-23, OXA-24, OXA-58 and OXA-143, and one subgroup (OXA-51) is intrinsic to A. baumannii (Opazo et al., 2012) . Additionally, cephalosporin resistance in A. baumannii is rising significantly because of the overexpression of the intrinsic AmpC cephalosporinase (Bou & Martínez-Beltrán, 2000) . From the phylogenetic analysis, the genes encoding these enzymes have a common ancestor and they are designated Acinetobacter-derived cephalosporinases (ADCs) (Perez et al., 2007) . bla ADC genes are generally expressed at low level; however, they are upregulated in the presence of a promoter upstream of the gene. Therefore, the presence of the ISAba1 sequence upstream of the chromosomal bla ADC genes in A. baumannii can lead to overexpression of the ADC-type b-lactamases (Dijkshoorn et al., 2007; Mahillon & Chandler, 1998) . The aim of this study was to characterize the carbapenem and cephalosporin resistance genes in A. baumannii clinical isolates and evaluate the presence of these genes in antibiotic resistance.
METHODS
Bacterial isolates. A total of 178 non-duplicate Acinetobacter clinical isolates were collected. The isolates were from patients admitted to Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia from October 2010 to April 2011. The sources of isolates were blood, sputum, tracheal aspirate, bronchoalveolar lavage, pus, sterile body fluid and urine.
Identification of the isolates. All isolates were identified by 16S rRNA and rpoB gene sequencing (Table 1) . DNA was extracted by the boiling method. PCR amplification for 16S rRNA was performed as follows: initial denaturation at 94 uC for 5 min; 30 cycles of denaturation at 94 uC for 30 s, annealing at 60.7 uC for 30 s, extension at 72 uC for 30 s; and final extension at 72 uC for 5 min. The rpoB gene was amplified with the following conditions: initial denaturation at 95 uC for 5 min; 35 cycles of denaturation at 95 uC for 30 s, annealing at 52 uC for 40 s, extension at 72 uC for 30 s; and final extension at 72 uC for 5 min. PCR products were purified using the Wizard SV Gel and PCR Clean-Up System (Promega) according to the manufacturer's instructions. The purified products were subjected to sequencing using the GENOMELAB DTCS Quick Start kit (Beckman Coulter) and an automated sequencer (Beckman Coulter). Sequences were analysed using the BLAST network service at the National Center for Biotechnology Information. , bla OXA-51-like and bla ADC consisting of all six primers was carried out with the following conditions: 16mM dNTP mixture, 10 pmol forward and reverse primer, 1 U Prime Taq DNA Polymerase (GENET BIO), template DNA and sterile water. The genes were amplified using iCycler Thermal Cycler (Bio-Rad Laboratories) with the amplification conditions as follows: initial denaturation at 94 uC for 5 min, 33 cycles of 94 uC for 30 s, 53 uC for 40 s and 72 uC for 30 s, and a final elongation at 72 uC for 5 min.
The PCR conditions for bla OXA-24-like and bla OXA-58-like were as follows: initial denaturation at 94 uC for 5 min, 33 cycles of 94 uC for 30 s, 43 uC for 40 s and 72 uC for 30 s, and a final elongation at 72 uC for 5 min. The PCR conditions for bla IMP and bla VIM were as follows: initial denaturation at 95 uC for 5 min, 33 cycles of 95 uC for 30 s, 47 uC for 45 s and 72 uC for 30 s, and a final elongation at 72 uC for 5 min.
To detect the presence of ISAba1 upstream of bla OXA-51 , bla OXA-23 and bla ADC , PCR amplification was carried out using a reverse primer for the bla gene and a forward primer for ISAba1 (Table 1) . ISAba1 upstream of bla OXA-51 and bla OXA-23 were amplified using the following conditions: initial denaturation at 95 uC for 2 min, 35 cycles of 95 uC for 10 s, 50 uC for 10 s and 72 uC for 130 s, and a final elongation at 72 uC for 60 s. The conditions for amplification of ISAba1 of blaAmpC were as follows: initial denaturation at 94 uC for 90 s, 30 cycles of 94 uC for 30 s, 53 uC for 30 s and 72 uC for 60 s, and a final elongation at 72 uC for 10 min.
Amplified PCR products were purified using a gel extraction kit (GeneJET; Thermo Scientific) and submitted for sequencing to a commercial company (First Base Laboratories) for nucleotide sequence confirmation.
Statistical analysis. Statistical analysis was performed using the Statistical Package for the Social Sciences for Windows (version 18.0; SPSS). Parametric variables were assessed using the chi-squared test, as appropriate. A difference was considered statistically significant if the P-value was less than 0.05.
RESULTS

Bacterial population
Analysis of the 16S rRNA and rpoB sequences showed that Acinetobacter clinical isolates were assigned to eight distinct Acinetobacter genospecies: A. baumannii (n5167), A. pitti (n52), A. haemolyticus (n51), A. schindleri (n51), A. ursingii (n51), A. bereziniae (n51), A. junnii (n51) and A. nosocomialis (n54). Further investigations were carried out on A. baumannii only, due to the fact that the majority of this species were isolated from clinical samples. The A. baumannii strains were isolated from 105 male (62.9 %) and 62 female (37.1 %) patients. The median age of the patients was 57.5±21.9 years, with a range from new born to 88 years. A. baumannii was isolated from different specimens as follows: soft tissue/wound (74; 44.3 %), respiratory samples (54; 32.3 %), urine (17; 10.2 %), blood (7; 4.2 %), sterile body fluid (4; 2.4 %) and others (11; 6.6 %). The distribution of A. baumannii isolates from different wards was 54 (32.3 %), 30 (18 %), 28 (16.8 %), 24 (14.4 %) and 31 (18.6 %) patients in the ICU, Medical, Orthopaedic, Surgery and other wards, respectively.
Antimicrobial susceptibility profiles
The susceptibility profiles of 167 A. baumannii isolates towards imipenem, meropenem, cefepime and ceftazidime were determined by the E-test method. As shown in Table  2 , MIC values of the antibiotics show that 73-76.6 % of the A. baumannii isolates were nonsusceptible to all four antibiotics tested. MIC 50 and MIC 90 of the antibiotics show that A. baumannii were highly resistant to carbapenems and cephalosporins, with MIC values of .32 and .256 mg l 21 , respectively. Nonsusceptible A. baumannii were isolated mainly from the ICU (46), followed by Medical ward (24), Orthopaedic ward (24) and Surgery ward (13).
Detection of carbapenemase genes
Resistance genes for carbapenems among A. baumannii were detected in 97 (162), 82 (137) and 8.4 % (14) for bla OXA-51-like , bla OXA-23-like and bla IMP , respectively. Nucleotide sequences of the genes were identical to the sequences in the GenBank database (bla OXA-51 , accession no. KF048918.1; bla OXA-23 , accession no. KJ716226.1; bla IMP , accession no. DQ307573.1). bla OXA-58-like , bla OXA-24-like and bla VIM were not detected in any of the isolates. As shown in Table 3 , the bla OXA-51-like gene was identified in most of the isolates i.e. 97.7 % (128 of 131) of the nonsusceptible A. baumannii and 94.4 % (34 of 36) of the susceptible A. baumannii. Among the isolates harbouring bla OXA-51-like , ISAba1 was detected in 46.3 % (75 of 162) of the isolates. Seventy-three of the isolates harbouring ISAba1-bla were nonsusceptible to carbapenems. Furthermore, ISAba1-bla OXA-51 was not detected in 55 of 128 carbapenemnonsusceptible A. baumannii isolates. bla OXA-23-like genes were detected in 95.4 % (125 of 131) of nonsusceptible A. baumannii and ISAba1 was detected in all of these isolates. In addition, 33.3 % (12 of 36) of the susceptible A. baumannii harbouring bla OXA-23 and ISAba1 upstream to bla OXA-23 were detected in three of these isolates. The bla IMP gene was present more in susceptible A. baumannii (25 %; 9 of 36) than in nonsusceptible A. baumannii (3.8 %; 5 of 131). 
Detection of cephalosporinase genes
As shown in Table 4 , a total of 85.6 % (143 of 167) of A. baumannii isolates harboured the bla ADC gene and the gene was present in 93.7 % (119 of 127) of cephalosporinnonsusceptible A. baumannii isolates. Sequence analyses of the amplified product confirmed its identity as the bla ADC gene (GenBank accession no. JX169789.1). The bla ADC gene was also detected in 60 % (24 of 40) of cephalosporinsusceptible strains. Eighty-four (58.7 %) and 115 (80.4 %) isolates harbouring bla ADC had MICs of .256 mg l 21 for cefepime and ceftazidime, respectively. ISAba1-bla ADC was detected in 85.8 % (109 of 127) of cephalosporin-nonsusceptible A. baumannii isolates. ISAba1 was not detected in 8.4 % (10 of 119) nonsusceptible A. baumannii isolates harbouring bla ADC . In addition, the ISAba1-bla ADC was detected in 32.5 % (13 of 40) of cephalosporin-susceptible A. baumannii isolates. The presence of ISAba1 upstream of the bla ADC in A. baumannii significantly correlated with nonsusceptibility to cephalosporins (Yates' continuity correction, P,0.0001).
DISCUSSION
This study analysed the carbapenemase and cephalosporinase genes of A. baumannii clinical isolates which are responsible for resistance to carbapenems and cephalosporins. The MIC results showed that the majority of the isolates were highly resistant to imipenem, meropenem, ceftazidime and cefepime. We observed more than 70 % of A. baumannii clinical isolates were resistant to carbapenems and cephalosporins. A clear correlation was identified between the presence of ISAba1-bla OXA-23 and carbapenem resistance. In addition, ISAba1-bla ADC was significantly associated with cephalosporin resistance.
Overall, bla OXA-51-like genes were the most prevalent subgroup and these genes were detected in 97 % of the A. baumannii isolates, irrespective of the carbapenem susceptibility or resistance. A study suggested that ISAba1 is providing the promoter for bla OXA-51-like genes and was associated with carbapenem resistance (Turton et al., 2006a) . However, the results of our study showed that the presence of ISAba1 upstream of bla OXA-51-like was detected among susceptible and nonsusceptible A. baumannii isolates, indicating that this IS element does not influence the regulation of the bla OXA-51-like gene. The detection of bla OXA-51-like genes in almost all A. baumannii (97 %) was consistent with the view that they are intrinsic to A. baumannii, similar to the findings reported by others (Héritier et al., 2005; Woodford et al., 2006) . That bla OXA-51-like genes were not detected in 3 % of the A. baumannii might be due to sequence variation at the primer annealing site due to the presence of other variants of bla OXA-51 in these isolates. Many variants of bla OXA-51 have been described, and a possible limitation of this PCR is whether it can detect every variant. The design of primers should detect all the variants with the possible exception of bla , where there is a single base mismatch with the forward primer in bla OXA-75 (Turton et al., 2006b ).
This study showed that the presence of ISAba1-bla OXA-23 was sufficient to confer resistance even without the assistance of other oxacillinase genes. The nonsusceptible characteristic is due to the presence of ISAba1-bla OXA-23 in these isolates. However, detection of ISAba1-bla OXA-23 in three isolates with carbapenem susceptibility might be due to the downregulation of the IS element in these isolates or gene truncation at the 59 terminus downstream of the bla OXA-23 gene (Wang et al., 2014) . Production of OXA-23 is the most frequently encountered mechanism of carbapenem resistance in A. baumannii worldwide (Perez et al., 2007) and the resistance phenotype in our isolates was likely accentuated by the presence of strong promoter sequences provided by ISAba1, leading to overproduction of the enzyme (Corvec et al., 2007) . The OXA-23-like enzymes are encoded by bla OXA-23-like genes on plasmids or chromosomes and are associated with the presence of ISAba1, which contributes to carbapenem resistance. The plasmid-borne carbapenemases are easily spread to other genera or species and can occur inter-or intra-specifically in hospital environments, so it is important to develop control strategies to prevent infections caused by carbapenem-resistant A. baumannii. This strategy should help in the prevention of nosocomial spread of infections, especially among immunocompromised patients.
The absence of bla OXA-58-like and bla OXA-24-like genes in our clinical isolates is consistent with the reports from other studies of the same region, which showed that these two genes were not implicated in carbapenem resistance (Kong et al., 2012; Lean et al., 2014) . Furthermore, detection of bla IMP in a minority of the isolates and the absence of bla VIM showed that metallo-b-lactamases were not the predominant b-lactamases in our clinical A. baumannii isolates.
Our results indicated that more than 80 % of ISAba1-bla ADC -harbouring A. baumannii isolates were nonsusceptible to ceftazidime and cefepime. However, several A. baumannii isolates with ISAba1-bla ADC remained susceptible to cephalosporins. It is likely that differences in transcriptional-level regulation of bla ADC could affect the cephalosporin susceptibility in different A. baumannii strains (Lopes et al., 2011) . ISAba1-bla ADC was not detected in fewer than 10 % of the nonsusceptible isolates, suggesting that alternative mechanisms may be responsible for resistance to extended-spectrum cephalosporins (Bratu et al., 2008; Danes et al., 2002) .
In conclusion, we showed that the clinical isolates of A. baumanni in our hospital contained antibiotic resistance genes to combat carbapenems and cephalosporins. Carbapenem and cephalosporin resistance is manifested largely by the presence of ISAba1-bla OXA-23 and ISAba1-bla ADC genes, respectively. This is, we believe, the first report from our setting to characterize the antibiotic resistance genes in A. baumannii clinical isolates. Continuous surveillance of resistant A. baumannii and elucidation of their antibiotic resistance mechanisms in the hospital are crucial to help develop effective therapy regimens and to prevent further dissemination of these resistance strains.
